dc.contributor.author |
Lin, HS |
en |
dc.contributor.author |
Turner, DJ |
en |
dc.contributor.author |
Srivastava, A |
en |
dc.contributor.author |
Jameson, Michael |
en |
dc.date.accessioned |
2017-04-25T22:49:01Z |
en |
dc.date.available |
2016-07-06 |
en |
dc.date.issued |
2016-07-09 |
en |
dc.identifier.citation |
Journal of Gerontology & Geriatric Research, 09 July 2016, 5 (4), Article number 1000318 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/32658 |
en |
dc.description.abstract |
Objectives: The benefit of adding oxaliplatin to adjuvant fluoropyrimidine chemotherapy in patients >70 years is controversial. This retrospective audit investigated usage, benefit and tolerability of adjuvant chemotherapy for colon cancer in older adults. Materials and methods: Patients aged >60 years with stage III colon cancer referred for adjuvant chemotherapy between 2010–2012 were identified from a tertiary hospital oncology database. Data were collected on demographics, chemotherapy received, completion rates, toxicities, relapse and survival. Comparison was made between the older group (age >70 years) and the younger group (age 60-70 years). Results: 95 eligible patients were identified; 50 in the older group (median age 76), 45 in the younger group (median age 66), 56% male, 82% NZ European and 5% Maori. Older patients were less likely to receive adjuvant chemotherapy (76% and 91% in the older and younger group respectively, p=0.0017), especially oxaliplatincontaining regimens (14% and 47% of older and younger groups, respectively). Similar proportions in each group completed >80% of planned chemotherapy doses with no significant difference in early discontinuation due to toxicities. Survival was poorer in the older group (HR=2.90, 95% CI 1.40-5.47), including those who received chemotherapy (HR=3.22, 95% CI 1.42-6.88) but there was no significant difference in relapse-free survival between older and younger patients. Conclusion: Adjuvant chemotherapy was commonly offered to older adults with stage III colon cancer, although oxaliplatin was largely restricted to younger patients. While relapse-free survival was similar between age groups and chemotherapy types, older patients had poorer survival despite adjuvant chemotherapy. |
en |
dc.language |
English |
en |
dc.publisher |
Omics Publishing Group |
en |
dc.relation.ispartofseries |
Journal of Gerontology & Geriatric Research |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/2167-7182/
https://www.omicsgroup.org/journals/instructionsforauthors-gerontology-geriatric-research-open-access.php |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.rights.uri |
https://creativecommons.org/licenses/by/4.0/ |
en |
dc.title |
The Benefit and Tolerability of Adjuvant Chemotherapy in Elderly Stage III Colon Cancer Patients: A 3 Year Retrospective Audit |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.4172/2167-7182.1000318 |
en |
pubs.issue |
4 |
en |
pubs.volume |
5 |
en |
dc.description.version |
VoR - Version of Record |
en |
pubs.author-url |
https://www.omicsgroup.org/journals/the-benefit-and-tolerability-of-adjuvant-chemotherapy-in-elderly-stage-iii-colon-cancer-patients-a-3-year-retrospective-audit-2167-7182-1000318.php?aid=77055 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
606731 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
School of Medicine |
en |
pubs.org-id |
Waikato Clinical school |
en |
dc.identifier.eissn |
2167-7182 |
en |
pubs.number |
1000318 |
en |
pubs.record-created-at-source-date |
2017-01-15 |
en |